Janagliflozin Treat T2DM Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 442 participants.
Also called NCT03811548
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 442 participants
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Registry
-
NCT03811548
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03811548. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-23 (actual); primary completion 2020-06-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Janagliflozin Treat T2DM Monotherapy
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Janagliflozin 25mg
- Intervention (Drug)
- Janagliflozin 50mg
- Intervention (Drug)
- Placebo/Janagliflozin
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Record details
- Record id
cardio:ct-nct03811548- Content hash
7646b3f2417dfc092e5bc992f66a3b7b54af1194397b60f584c8dfa84e8fff73